734 related articles for article (PubMed ID: 18823036)
1. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
3. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
[TBL] [Abstract][Full Text] [Related]
6. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
7. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Meleis L; Moore R; Inman BA; Harrison MR
J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
[TBL] [Abstract][Full Text] [Related]
11. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
[TBL] [Abstract][Full Text] [Related]
12. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
[TBL] [Abstract][Full Text] [Related]
14. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
16. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
[TBL] [Abstract][Full Text] [Related]
18. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]